Clinical Trial Update: Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating a triple-drug regimen consisting of mosunetuzumab, polatuzumab vedotin, and lenalidomide for relapsed/refractory diffuse …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma
• Transformed Indolent B-cell Non-hodgkin Lymphoma

Drugs mentioned

• LUNSUMIO (mosunetuzumab)
• Polivy (polatuzumab vedotin)
• Revlimid (lenalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 1 | Status: RECRUITING